• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Microchip imaging platform for roundworms could accelerate research

October 11, 2016 By Sarah Faulkner

roundworms-1x1Researchers developed a microchip imaging platform to image-analyze thousands of roundworms simultaneously, according to the Cockrell School of Engineering at the University of Texas at Austin. This is the 1st large-scale, in vivo drug discovery platform using a whole animal model, the school reported.

The study, published in Nature Communications, detailed a flexible, cellphone-sized chip with 96 wells used to immobilize drug-treated roundworms, commonly referred to as C. elegans. The chip can be used by researchers to analyze the efficacy of drugs on 3,600 live worms, at the cost of an in vitro, cell-based platform.

C. elegans are the 1st multicellular organisms to have a completely sequenced genome, the school reported. Because about 1/3 of C. elegans’ genes are the same as disease-causing genes in humans, the creatures serve as an effective model to evaluate the efficacy of drugs. The researchers at the University of Texas at Austin specifically focused on drugs that are indicated for neurodegenerative diseases, since the roundworms have full nervous systems and a diverse group of neurons.

“The C. elegans are thousands of times bigger than cells, so now that we have developed a way to capture and immobilize so many of them so quickly, we can determine much more information about the efficacy of drugs in a whole organism rather than the limited information that is derived when we used isolated individual cells,” lead researcher Adela Ben-Yakar said in prepared remarks.

They analyzed 1,000 drugs for treating protein aggregation, a characteristic of neurodegenerative diseases such as Huntington’s disease. “Four of the drugs we tested were effective at treating a protein aggregation model that is directly related to Huntington’s, and one of these drugs became even more effective at increased doses without causing toxicity,” Ben-Yakar said.

Ben-Yakar’s start-up company, Newormics, is developing a commercial product from the imaging prototype, according to the university.

Filed Under: Discovery, Featured, Imaging, Neurological, Research & Development Tagged With: University of Texas at Austin

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS